OncoMatch/Clinical Trials/NCT06138275
Elranatamab in R/R Multiple Myeloma
Is NCT06138275 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Elranatamab for refractory multiple myeloma.
Treatment: Elranatamab — This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CAR-T cell therapy (idecabtagene vicleucel) — standard of care
Previously treated relapsed and refractory multiple myeloma following idecabtagene vicleucel as infusion as standard of care who have achieved at least a PR or better per IMWG criteria. Patients will have received idecabtagene per label including after at least 4 prior lines of therapy and relapsed after an immunomodulatory drug (IMiD), a proteasome inhibitor and an Anti-CD38 monoclonal antibody
Must have received: immunomodulatory drug
relapsed after an immunomodulatory drug (IMiD)
Must have received: proteasome inhibitor
relapsed after ... a proteasome inhibitor
Must have received: Anti-CD38 monoclonal antibody
relapsed after ... an Anti-CD38 monoclonal antibody
Cannot have received: anti-BCMA bispecific antibody
Previous treatment with an anti-BCMA (B-cell maturation antigen) bispecific antibody
Cannot have received: stem cell transplant
Exception: within 12 weeks prior to enrollment
Stem cell transplant within 12 weeks prior to enrollment
Cannot have received: investigational drug
Exception: within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Lab requirements
Blood counts
Absolute neutrophil count ≥1000/mcL (G-CSF permitted if completed ≥7 days prior); Platelet count ≥25,000/mcL (transfusion permitted if completed ≥7 days prior); Hemoglobin ≥8 g/dL (transfusion permitted if completed ≥7 days prior)
Kidney function
Calculated creatinine clearance ≥30 mL/min by Cockcroft-Gault equation
Liver function
Serum total bilirubin <2 mg/dL (Gilbert's syndrome exception: <3 mg/dL and normal direct bilirubin); ALT and/or AST <2.5 × ULN
Cardiac function
LVEF ≥40% by MUGA or ECHO
Participants must meet the following organ and marrow function as defined below: ... Serum total bilirubin <2 mg/dL; and ... ALT and/or AST <2.5 × ULN ... Calculated creatinine clearance ≥30 mL/min ... Absolute neutrophil count ≥1000/mcL ... Platelet count ≥25,000/mcL ... Hemoglobin ≥8 g/dL ... LVEF ≥40% as determined by a multiple gated acquisition scan (MUGA) scan or echocardiogram (ECHO).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Beth-Israel Deaconess Medical Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify